The Antagonist Art Movement is a cultural movement formed in New York, New York in 2000. The group grew ... and resources. The Antagonist Movement has worked with more than 3,000 artists from around the world over the past 11 years. Overview Antagonist activities have included public gatherings, demonstrations ... East Side , the Antagonist Movement has participants in other US cities, Europe and South America. Influenced by the punk rock and pop art and by the Dada movement , the Antagonist Movement seeks ... of the Antagonist Movement while working in bars in the Lower East Side. They wanted to create an event ... night have included Bryan Middleton, Richard Allen and Brother Mike Cohen. Minsker took the helm of the Antagonist ... between 8 pm and 9 pm and stayed up until 2 am. The Antagonist took a 20 commission on art ... each other. ref cite web url http animalnewyork.com 2006 05 the antagonist movement ignite title ... from 8 pm to 10 pm, free live shows were performed in the back of Niagara bar under the banner of the Antagonist ... also composed music for two Antagonist films, This Is Berlin, Not New York and The Dolls of Lisbon ... of the books published by the Antagonist Movement. Currently the Monday music night has moved to Motor ... on the theme. Themes are determined by a combination of curators, artists, and members of the Antagonist ... was exhibited in the front room of Niagara bar and is featured in the Antagonist movie Mark of the Ninja. Gallery shows From time to time, the Antagonist Movement holds group art shows in small commercial ..., the Mindy Wyatt Gallery presented a curated group show of select artists of the Antagonist Art Movement ... of Lisbon The Antagonist Art Movement combined the efforts of artists all over the world to put together ... in 2007, the Antagonist began actively developing cultural exchanges with artists in other countries. Antagonist artists traveled to Germany in 2007 and to Portugal in 2010. The Antagonists are planning a group trip to Ecuador in 2013. In addition, the Antagonist Movement is actively seeking contacts ... more details
An opioid antagonist is a receptor antagonist that acts on opioid receptor s. Naloxone and naltrexone are commonly used opioid antagonist drugs which are competitive antagonist s that bind to the opioid receptors with higher affinity than agonists but do not activate the receptors. This effectively blocks the receptor, preventing the body from responding to opiates and endorphins. Some opioid antagonists are not pure antagonists but in fact do produce some weak opioid partial agonist effects, and can produce analgesic effects when administered in high doses to opioid naive individuals. Examples of such compounds include nalorphine and levallorphan . However the analgesic effects from these drugs are limited and tend to be accompanied by dysphoria , most likely due to action at the kappa opioid receptor . As they induce opioid withdrawal effects in people who are taking, or have recently used, opioid full agonists, these drugs are considered to be antagonists for practical purposes. The weak partial agonist effect can be useful for some purposes, and has previously been used for purposes such as long term maintenance of former opioid addicts using nalorphine, however it can also have disadvantages such as worsening respiratory depression in patients who have overdosed on non opioid sedatives such as Alcoholic beverage alcohol or barbiturates . Naloxone on the other hand has no partial agonist effects, and is in fact a partial inverse agonist at mu opioid receptors, and so is the preferred ... Cyprodime is a selective mu opioid receptor antagonist Naltrindole is a selective delta opioid receptor antagonist Norbinaltorphimine is a selective kappa opioid receptor antagonist Other selective ... House episode Skin Deep , opioid antagonist drugs were administered in order to completely remove ... partial agonist and antagonist actions External links David S, Lancaster T, Stead LF. http www.cochrane.org ... References Reflist DEFAULTSORT Opioid Antagonist Category Opioid antagonists de Opioidantagonist ... more details
About the biochemistry term other uses Antagonist disambiguation File Antagonist 2.png thumb Antagonists ... produced by a receptor agonist coupling. A receptor antagonist is a type of Receptor biochemistry ... of the receptor s activity. Antagonist activity may be reversible or irreversible depending on the longevity of the antagonist receptor complex, which, in turn, depends on the nature of antagonist ... pmid 12690954 doi 10.1080 10606820214640 ref The term antagonist was originally coined to describe ... 1866283 ref The biochemical definition of a receptor antagonist was introduced by Ariens ref cite journal ... article. ref in the 1950s. The current accepted definition of receptor antagonist is based on the Receptor ... activation and receptor theory and the biochemical definition of a receptor antagonist continues ... . In functional antagonist assays, a dose response curve measures the effect of the ability ... The potency of an antagonist is usually defined by its IC50 IC sub 50 sub value. This can be calculated for a given antagonist by determining the concentration of antagonist needed to elicit half ... 10.1111 j.1365 2885.2004.00620.x ref The lower the IC sub 50 sub the greater the potency of the antagonist ... doi 10.1038 nrd1500 ref Affinity The affinity of an antagonist for its binding site K sub i sub , i.e. .... The affinity of an antagonist can be determined experimentally using Schild regression or for competitive ... of a competitive antagonist as determined on a dose response curve. Altering the amount of antagonist ... dose ratio 1 versus the log concentration of antagonist for a range of antagonist concentrations ... the line cuts the x axis on the regression plot. Whereas, with Schild regression, antagonist ... by the Cheng Prusoff factor used to calculate the K sub i sub affinity constant for an antagonist ... Competitive Competitive antagonist s also known as surmountable antagonists reversibly bind to receptors ..., an antagonist will block agonist binding. The level of activity of the receptor will be determined ... more details
A Cholecystokinin antagonist is a specific type of receptor antagonist which blocks the receptor sites for the peptide hormone Cholecystokinin Cholecystokinin receptor CCK . There are two subtypes of this receptor known at present, defined as cholecystokinin A receptor CCK sub A sub and cholecystokinin B receptor CCK sub B sub also called CCK 1 and CCK 2 . CCK sub A sub is mainly expressed in the small intestine, and is involved in the regulation of enzyme secretion by the pancreas, secretion of gastric acid in the stomach, intestinal motility and signalling of satiety fullness . CCK sub B sub is expressed mainly in the central nervous system, and has functions relating to anxiety and the perception of pain. ref cite journal pmid 15533776 year 2004 last1 Rehfeld first1 JF title Clinical endocrinology and metabolism. Cholecystokinin volume 18 issue 4 pages 569 86 doi 10.1016 j.beem.2004.07.002 journal Best practice & research. Clinical endocrinology & metabolism ref Antagonists for the CCK receptors can thus have multiple functions in both the gut and brain. The best known CCK antagonist is the non selective antagonist proglumide , which blocks both CCK sub A sub and CCK sub B sub , and was originally developed for the treatment of stomach ulcers. This action derived from its blockade of CCK sub A sub in the gut and consequent reduction in secretion of gastric acid, however an interesting side effect of proglumide was found, namely that it increases the analgesic effects of opioid ... A first3 G first4 J first5 M first6 E first7 D ref However by far the main focus of CCK antagonist research ... of non peptide CCK2 receptor agonist and antagonist ligand volume 7 issue 12 pages 1195 204 journal ... are also expressed in the brain to some extent, and interestingly IQM 95333, an antagonist selective ... L pez title Pharmacological evaluation of IQM 95,333, a highly selective CCKA receptor antagonist ... Category Cholecystokinin antagonists sr Holecistokininski antagonist ... more details
An orexin antagonist is a drug that inhibits the effect of orexin by acting as a receptor antagonist of the orexin receptor . Potential applications include treatment of sleep disorders such as insomnia . ref name pmid18673167 cite journal author Roecker AJ, Coleman PJ title Orexin receptor antagonists medicinal chemistry and therapeutic potential journal Curr Top Med Chem volume 8 issue 11 pages 977 87 year 2008 pmid 18673167 doi ref ref name pmid21170610 cite journal author Cao M, Guilleminault C title Hypocretin and its emerging role as a target for treatment of sleep disorders journal Curr Neurol Neurosci Rep volume 11 issue 2 pages 227 34 year 2011 month April pmid 21170610 doi 10.1007 s11910 010 0172 9 url ref Examples Almorexant , development of the drug was abandoned in January 2011 SB 334,867 , has been shown to produce sedative and anorectic effects in animals, ref name pmid11298806 cite journal author Rodgers RJ, Halford JC, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JR, Upton N, Porter RA, Johns A, Blundell JE title SB 334867, a selective orexin 1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin A in rats journal Eur. J. Neurosci. volume 13 issue 7 pages 1444 52 year 2001 month April pmid 11298806 doi 10.1046 j.0953 816x.2001.01518.x ref SB 408,124 SB 649,868 , in development for potential use in sleep disorders Suvorexant , in development for potential use in sleep disorders TCS OX2 29 References reflist Category Orexin antagonists ... more details
A Prostaglandin antagonist is a hormone antagonist acting upon prostaglandin . NSAID s inhibit cyclooxygenase and reduce prostaglandin synthesis. Corticosteroid s inhibit phospholipase A sub 2 sub production by boosting production of lipocortin , an inhibitor protein. Relatively new drugs, known as COX 2 selective inhibitor s or coxibs, are used as specific inhibitors of COX 2. The development of these drugs allowed the circumvention of the negative gastrointestinal effects while effectively reducing inflammation. Adverse effects Both NSAIDs and Coxibs can raise the risk of myocardial infarction , when taken on a chronic basis for at least 18 months. One emerging hypothesis that may explain the cardiovascular effects is that coxibs create an imbalance in circulating TxA2 thromboxane and PGI2 prostacyclin levels. An increased in the ratio of TxA2 PGI2 could lead to increased platelet aggregation and dysregulation of platelet homeostasis. ref Cheng Y et al., Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002 296 539 51. PMID 11964481. ref See also Mechanism of action of aspirin References references External links MeshName Prostaglandin antagonists Hormone antagonists Biochemistry stub Category Corticosteroids Category Receptor antagonists Category Prostaglandins ... more details
DISPLAYTITLE H sub 2 sub antagonist Image Cimetidine xtal 3D balls.png thumb Ball and stick model of cimetidine , the prototypical H sub 2 sub receptor antagonist. The H sub 2 sub receptor antagonists are a class of medication drugs used to block the action of histamine on parietal cell s in the stomach , decreasing the production of acid by these cells. H sub 2 sub antagonists are used in the treatment of dyspepsia , although they have been surpassed in popularity by the more effective ref Eriksson S, L ngstr m G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2 receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis a meta analysis published correction appears in Eur J Gastroenterol Hepatol. 1996 8 192 . Eur J Gastroenterol Hepatol. 1995 7 467 475 ref proton pump inhibitor s. In the United States, all four Food and Drug Administration FDA approved ... the counter drug over the counter in relatively low doses. The prototypical H sub 2 sub antagonist ... . History and development Cimetidine was the prototypical histamine H sub 2 sub receptor antagonist ... to develop a histamine receptor receptor antagonistantagonist that would suppress stomach acid ... antagonist traditional antihistamine s had no effect on acid production. From these facts the SK&F ..., a partial H sub 2 sub receptor antagonist. From this lead the receptor model was further refined and eventually led to the development of burimamide , a specific competitive antagonist at the H ... the first clinically successful H sub 2 sub antagonist. Ranitidine common brand name Zantac was developed ... sub 2 sub receptors are blocked. Like the H1 antagonist H sub 1 sub antihistamines , the H sub 2 sub antagonists are inverse agonist s rather than true receptor antagonist s. Citation needed date ... 7 1378 ref The H2 antagonist Ranitidine is prescribed by some urologists for patients with interstitial ... sv H2 antagonist th 2 tr H resept r antagonisti ... more details
A nicotinic antagonist is a type of anticholinergic that inhibits the action at nicotinic acetylcholine receptor s. These compounds are mainly used for peripheral muscle paralysis in surgery, but some centrally acting compounds such as bupropion , mecamylamine , and 18 methoxycoronaridine block nicotinic acetylcholine receptors in the brain and can be used for treating drug addiction . class wikitable Comparison Mechanism Antagonist Preferred receptor Clinical use rowspan 3 Ganglionic blocking agents Hexamethonium Ganglion type nicotinic receptor Ganglion type none ref name Rang149 cite book author Rang, H. P. title Pharmacology publisher Churchill Livingstone location Edinburgh year 2003 pages isbn 0 443 07145 4 oclc doi Page 149 ref Mecamylamine Ganglion type nicotinic receptor Ganglion type Trimethaphan Ganglion type nicotinic receptor Ganglion type Rarely used for blood pressure decrease during surgery ref name Rang149 rowspan 6 Nondepolarizing neuromuscular blocking agents Atracurium Muscle type nicotinic receptor Muscle type muscle relaxant in anaesthesia ref name Rang149 Doxacurium Muscle type nicotinic receptor Muscle type Mivacurium Muscle type nicotinic receptor Muscle type Pancuronium Muscle type nicotinic receptor Muscle type muscle relaxant in anaesthesia ref name Rang149 Tubocurarine Muscle type nicotinic receptor Muscle type Rarely used ref name Rang149 Vecuronium Muscle type nicotinic receptor Muscle type muscle relaxant in anaesthesia ref name Rang149 rowspan 1 Depolarizing neuromuscular blocking agents Suxamethonium chloride Succinylcholine Muscle type nicotinic receptor Muscle type rowspan 1 Centrally acting nicotinic antagonists 18 Methoxycoronaridine alpha3beta4 nicotinic 3 4 See also Nicotinic agonist References Reflist 2 External links MeshName Nicotinic antagonists Receptor agonists and antagonists Antiaddictives Antihypertensives and diuretics Muscle relaxants Cholinergics Category Nicotinic antagonists antihypertensive stub musculoskeletal ... more details
A leukotriene antagonist sometimes referred to as a leukast is a drug that inhibits leukotriene s, which are fatty compounds produced by the immune system that cause inflammation in asthma and bronchitis , and constrict airways. Leukotriene inhibitors or modifiers , such as montelukast , zafirlukast , Pranlukast and zileuton , are used to treat those diseases. They are less effective than corticosteroids and thus less preferred in the treatment of asthma. ref cite journal author Fanta CH title Asthma journal N Engl J Med volume 360 issue 10 pages 1002 14 year 2009 month March pmid 19264689 doi 10.1056 NEJMra0804579 ref Approaches There are two main approaches to block the actions of leukotrienes. Inhibition of the 5 lipoxygenase pathway Drugs such as zileuton block 5 lipoxygenase , inhibiting the synthetic pathway of leukotriene metabolism, whereas drugs such as MK 886 block the 5 lipoxygenase activating protein FLAP and may help in treating atherosclerosis . ref name Jawien2006 cite journal last1 Jawien first1 J. last2 Gajda first2 M. last3 Rudling first3 M. last4 Mateuszuk first4 L. last5 Olszanecki first5 R. last6 Guzik first6 T. J. last7 Cichocki first7 T. last8 Chlopicki first8 S. last9 Korbut first9 R. title Inhibition of five lipoxygenase activating protein FLAP by MK 886 decreases atherosclerosis in apoE LDLR double knockout mice journal European Journal of Clinical Investigation volume 36 issue 3 pages 141&ndash 146 year 2006 month March pmid 16506957 doi 10.1111 j.1365 2362.2006.01606.x ref Antagonism of cysteinyl leukotriene type 1 receptors Agents such as montelukast and zafirlukast block the actions of cysteinyl leukotrienes at the CysLT1 receptor on target cells such as bronchial smooth muscle. These modifiers have been shown to improve asthma symptoms, reduce asthma exacerbations and limit markers of inflammation such as eosinophil counts in the peripheral blood and bronchoalveolar lavage fluid. This demonstrates that they have anti inflammatory properties ... more details
DISPLAYTITLE H sub 1 sub antagonist An H sub 1 sub antagonist is a histamine antagonist of the histamine H1 receptor H sub 1 sub receptor that serves to reduce or eliminate effects mediated by histamine , an endogenous chemical mediator released during allergy allergic reactions . Agents where the main therapeutic effect is mediated by negative modulation of histamine receptors are termed antihistamines other agents may have antihistaminergic action but are not true antihistamines. In common use, the term antihistamine refers only to H sub 1 sub antagonists, also known as H sub 1 sub receptor antagonists and H sub 1 sub antihistamines. It has been discovered that these H sub 1 sub antihistamines are actually inverse agonist s at the histamine H sub 1 sub receptor rather than receptor antagonist antagonists per se . ref Cite journal pmid 11972592 doi 10.1046 j.0954 7894.2002.01314.x title H sub 1 sub antihistamines inverse agonism, anti inflammatory actions and cardiac effects year 2002 month April author Leurs R, Church MK, Taglialatela M journal Clinical & Experimental Allergy volume 32 issue 4 pages 489 98 ref Pharmacology In type I hypersensitivity allergic reactions, an allergen a type of antigen interacts with and cross links surface IgE antibody antibodies on mast cell s and basophil s. Once the mast cell antibody antigen complex is formed, a complex series of events that eventually leads to cell degranulation and the release of histamine and other chemical mediators from the mast cell or basophil occurs. Once released, histamine can react with local or widespread tissues through histamine receptor s. Histamine, acting on H sub 1 sub receptors, produces itch pruritus , vasodilation , hypotension , Flushing physiology flushing , headache , tachycardia , bronchoconstriction , increase in vascular permeability , potentiation of pain , and more. ref Cite journal first ... dates date September 2010 DEFAULTSORT H1 Antagonist Category H1 receptor antagonists bs Antagonisti ... more details
entry on Dopamine Beta Hydroxylase Deficiency cite journal author Fu W, Shen J, Luo X, et al. title Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product stepholidine ...Infobox Disease Name Dopamine beta hydroxylase deficiency Image Dopamin Dopamine.svg Caption Dopamine beta hydroxylase is the enzyme responsible for converting dopamine pictured to norepinephrine . DiseasesDB 33227 ICD10 ICD9 ICDO OMIM 223360 MedlinePlus eMedicineSubj eMedicineTopic MeshID Dopamine beta hydroxylase deficiency is a condition involving inadequate Dopamine beta hydroxylase . Symptoms A deficiency of norepinephrine and epinephrine that causes orthostatic hypotension , nasal stuffiness, and droopy eyelids ptosis among other symptoms. Some people refer to this as norepinephrine deficiency. It s caused by largely increased amounts of serum dopamine and release of dopamine in place of norepinephrine. It is difficult for people with this to stand still for longer than one minute. Another ... dopamine . This can also have an impact on digestion. Dopamine has an emetic effect and inhibitis ... title Dopamine receptor antagonists publisher Pharmacorama date 2005 06 19 accessdate 2010 04 29 ref . People with dopamine beta hydroxylase deficiency may have a paradoxical response to NRI antidepressant ... in studying this disorder, as the persons generally have triple fold amounts of dopamine in their system ... title Dopamine Beta Hydroxylase Deficiency publisher GeneReviews NCBI Bookshelf date accessdate 2010 ... Robertson D, Hollister AS, Biaggioni I year 1990 chapter Dopamine b hydroxylase deficiency and cardiovascular ... JM, Rouet P title Dopamine beta hydroxylase deficiency journal Orphanet Journal of Rare Diseases volume ... url http www.ncbi.nlm.nih.gov bookshelf br.fcgi?book gene&part dbh title Dopamine Beta Hydroxylase ... SA, Perez Melgosa M, et al. title Dopamine beta hydroxylase deficiency impairs cellular immunity journal ...?view long&pmid 10051631 doi 10.1073 pnas.96.5.2274 Amino acid metabolic pathology DEFAULTSORT Dopamine ... more details
DISPLAYTITLE Dopamine receptor D sub 2 sub PBB geneid 1813 Dopamine receptor D sub 2 sub , also known ... sub 2 sub subtype of the dopamine receptor . This G protein coupled receptor inhibits adenylyl cyclase ... is normal or due to aberrant splicing. ref name entrez cite web title Entrez Gene DRD2 dopamine receptor ... JM, Saitou N, Sanders AR, Gelernter J, Gejman PV title Synonymous mutations in the human dopamine ... M title A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated ... for the dopamine D sub 2 sub receptor, but are, in general, very unselective, at best ... manner, older dopamine agonists used for Parkinson s disease such as bromocriptine and cabergoline are poorly selective for one dopamine receptor over another, and, although most of these agents do ... 2 sub partial agonist D sub 3 sub antagonist, with good selectivity over other receptors ref name pmid20153647 ... D, Arista L, Worby A, Watson SP title The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure journal Bioorganic & Medicinal Chemistry ... url ref Talipexole selective for D sub 2 sub over other dopamine receptors, but also acts as sub 2 sub adrenoceptor agonist and 5HT sub 3 sub antagonist. OSU 6162 D sub 2 sub partial agonist and 5 HT sub 2A sub partial agonist, acts as dopamine stabilizer Piribedil also D3 receptor agonist and 2 adrenergic receptor sub 2 sub adrenergic antagonist LSD in vitro, LSD was found to be a partial agonist and potentiates dopamine mediated prolactin secretion in lactotrophs. ref name pmid9698051 ... acid diethylamide LSD is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine ... D sub 2 sub antagonist Melperone D sub 2 sub antagonist but also 5HT sub 2A sub antagonist Risperidone D sub 2 sub antagonist but also 5HT sub 2A sub antagonist Ziprasidone D sub 2 sub antagonist but also 5HT sub 2A sub antagonist Raclopride Radiolabled C sup 11 sup raclopride is commonly employed ... more details
number of antipsychotic s have dopamine receptor antagonist ic effects. The theory, however, does not posit dopamine overabundance as a complete explanation for schizophrenia. Rather, the overactivation ... , has been found to Receptor antagonist antagonize dopamine binding particularly at Receptor biochemistry receptors known as Dopamine receptor D2 D sub 2 sub dopamine receptors ... is both an agonist and an antagonist at D sub 2 sub receptors. Furthermore, although dopamine ...Refimprove date August 2009 The dopamine hypothesis of schizophrenia or the dopamine hypothesis of psychosis ... observed in this disorder. Introduction Some researchers have suggested that dopamine systems in the mesolimbic pathway may contribute to the positive symptoms of schizophrenia whereas problems with dopamine ..., all structures indicated in this disease . 5 HT2C also regulates dopamine release in response ... 2009 , or by removing various genes COMT , Dopamine beta hydroxylase DBH , GPRK6 , RGS9 , RIIbeta ..., all induce a marked behavioural supersensitivity to dopamine and a marked rise in the number of dopamine D sub 2 sub receptors in the high affinity state for dopamine. ref name See2 This latter work ... the value of early intervention cannot be stressed enough. Discussion Evidence for the dopamine hypothesis Amphetamine , cocaine and similar drugs increase levels of dopamine in the brain and can cause ..., those treated with dopamine enhancing levodopa for Parkinson s disease can experience psychotic side ... or other dopamine like compounds, all given at doses at which control normal volunteers ..., patients diagnosed with schizophrenia show greater levels of dopamine release particularly in the striatum than non psychotic individuals. However, the acute effects of dopamine stimulants include euphoria ... in 1970s which suggested that the binding affinity of antipsychotic drugs for D sub 2 sub dopamine ... in 1976. ref cite journal author Creese I, Burt DR, Snyder SH title Dopamine receptor binding ... more details
DISPLAYTITLE Dopamine receptor D sub 1 sub PBB geneid 1812 Dopamine receptor D sub 1 sub , also known ... and expression of the gene for a human D sub 1 sub dopamine receptor journal Nature volume 347 issue ... D, Salon J, Bunzow JR, Civelli O title Cloning and expression of human and rat D sub 1 sub dopamine .... title Human dopamine D sub 1 sub receptor encoded by an intronless gene on chromosome 5 journal Nature ... issn ref Function This gene encodes the D sub 1 sub subtype of the dopamine receptor . The D sub 1 sub subtype is the most abundant dopamine receptor in the central nervous system. This G protein coupled ... dopamine receptor D2 dopamine receptor D sub 2 sub mediated events. ref Cite journal title D1 like and D2 like dopamine receptors synergistically activate rotation and c fos expression in the dopamine ... in two transcript variants of this gene. ref name entrez cite web title Entrez Gene DRD1 dopamine ... X, Zhang A. title Dopamine D sub 1 sub receptor ligands where are we now and where are we going ... by dopamine itself. ref name pmid18642350 Agonists Image D1 agonists.png thumbnail right 320px ... characterization of a new dopamine D1 receptor full agonist journal J. Med. Chem. volume 49 ... and selective dopamine D sub 1 sub agonist that maintains behavioral efficacy following repeated ... of a dopamine D sub 1 sub full agonist, A 86929 journal J. Am. Chem. Soc. volume 126 issue 7 pages ... 1 sub like over D sub 2 sub like receptors, structurally most closely related to ergoline based dopamine ... potent D1 dopamine agonists pmc 2941879 year 2010 month September journal Bioorg. Med. Chem. pages ... for other receptors ref name pmid18642350 acts as an antagonist at D sub 1 sub but as an agonist at D sub 5 sub Ecopipam SCH 39,166 a selective D sub 1 sub D sub 5 sub antagonist that was being developed as an anti obesity medication but was discontinued ref name pmid18642350 Risperidone Antagonist of Dopamine D1 and D2 family protiens Interactions Dopamine receptor D1 has been shown to Protein ... more details
DISPLAYTITLE Dopamine receptor D sub 5 sub PBB geneid 1816 D 1B dopamine receptor is a protein that in humans ... H, Merril CR title The human D5 dopamine receptor DRD5 maps on chromosome 4 journal Genomics volume ... ref name entrez cite web title Entrez Gene DRD5 dopamine receptor D5 url http www.ncbi.nlm.nih.gov ... journal author Polymeropoulos MH, Xiao H, Merril CR title The human D sub 5 sub dopamine receptor DRD5 ... 10.1016 0888 7543 91 90091 R ref This gene encodes the D sub 5 sub subtype of the dopamine receptor ... pmid9588624 cite journal author Sidhu A title Coupling of D sub 1 sub and D sub 5 sub dopamine receptors .... It has a 10 fold higher affinity for dopamine than the dopamine receptor D1 D sub 1 sub subtype. Pseudogene ..., however there are a number of ligands that are selective for D sub 1 5 sub over the other dopamine receptors. The recent development of a selective D sub 5 sub antagonist has allowed the action of D ... hexahydrodibenz d,g azecin 3 ol antagonist, moderate binding selectivity over D sub 1 sub ref name pmid16539400 cite journal author Mohr P, Decker M, Enzensperger C, Lehmann J title Dopamine ... 5,6,7,8,9,14 hexahydrodibenz d,g azecin 3 ol, the first picomolar D sub 5 sub selective dopamine receptor antagonist journal J. Med. Chem. volume 49 issue 6 pages 2110 2116 year 2006 pmid 16539400 ... hexahydrodibenz d,g azecin 3 ol. ref name pmid16539400 Interactions Dopamine receptor D5 has ... Jan. title Direct protein protein coupling enables cross talk between dopamine D5 and gamma aminobutyric ... accessdate laysummary laysource laydate quote ref See also Dopamine receptor References Reflist 2 Further reading refbegin 2 PBB Further reading citations cite journal author Missale C title Dopamine ... of three human D5 dopamine receptor genes journal Genomics volume 13 issue 4 pages 968 973 year 1992 ... Localization of the D5 dopamine receptor gene to human chromosome 4p15.1 p15.3, centromeric to the Huntington ... Sunahara RK title Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine ... more details
, a selective dopamine D4 receptor antagonist journal Neuropharmacology volume 49 issue 1 pages ..., selective and competitive antagonist at dopamine D4 receptors an in vitro and in vivo comparison with L ...DISPLAYTITLE Dopamine receptor D sub 4 sub PBB geneid 1815 The dopamine receptor D sub 4 sub is a G protein ... dopamine D4 receptor with high affinity for the antipsychotic clozapine journal Nature volume ... dopamine receptor subtypes, the D sub 4 sub receptor is activated by the neurotransmitter dopamine ... disease . The D sub 4 sub receptor is considered to be dopamine receptor D2 D sub 2 sub like ... Neve KA, Seamans JK, Trantham Davidson H title Dopamine receptor signaling journal J. Recept. Signal ..., Smeraldi E title Distribution of a novel mutation in the first exon of the human dopamine D4 receptor ... Munaf MR, Yalcin B, Willis Owen SA, Flint J title Association of the dopamine D4 receptor DRD4 ... at the human dopamine receptor D4 DRD4 gene locus journal Am. J. Hum. Genet. volume 74 issue ... of polymorphisms are the alleles with 6 to 10 repeats. 7R appears to react less strongly to dopamine ... dopamine D4 receptor variants journal J Neurochem volume 65 issue 3 pages 1157 1165 year 1995 month ... Meta analysis of the association between the 7 repeat allele of the dopamine D 4 receptor gene and attention ... E, Dmitrieva J title Population migration and the variation of dopamine D4 receptor DRD4 allele ... PB, Sorenson MD title Dopamine receptor genetic polymorphisms and body composition in undernourished ... ER, Nemanov L, Katz M, Belmaker RH title Dopamine D4 receptor D4DR exon III polymorphism associated ... association between the D4 dopamine receptor gene and measures of Novelty Seeking journal Nat. Genet ... Owen SA, Flint J. title Association of the dopamine D4 receptor DRD4 gene and approach related personality ..., Armbruster B, Watts VJ, Nichols DE title WAY 100635 is a potent dopamine D4 receptor agonist journal ... JM, Marsh K, Brioni JD title A 412997 is a selective dopamine D sub 4 sub receptor agonist in rats ... more details
of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction journal ...DISPLAYTITLE Dopamine receptor D sub 3 sub PBB geneid 1814 D 3 dopamine receptor is a protein that in humans ... D3 dopamine receptor gene journal Hum Genet volume 87 issue 5 pages 618 20 year 1991 month Oct pmid 1916765 pmc doi ref ref name entrez cite web title Entrez Gene DRD3 dopamine receptor D3 ... This gene encodes the D sub 3 sub subtype of the dopamine receptor . The D sub 3 sub subtype inhibits ... ref cite journal last Joyce first JN coauthors Millan, MJ title Dopamine D3 receptor agonists for protection ... al. title Antidepressant effects of pramipexole, a dopamine D3 D2 receptor agonist, and 7 OH DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats journal European Journal of Pharmacology ... prescription drugs bind to the D sub 3 sub receptor, notably including some of the newer dopamine ... of the amide function of the preferential dopamine D3 agonist R,R S32504 Improvements of affinity and selectivity ..., a class of potent dopamine D3 receptor ligands journal J. Pharm. Pharmacol. volume 58 ..., Gardner EL title The selective dopamine D3 receptor antagonists SB 277011A and NGB 2904 and the putative ... P title Interactive SAR studies rational discovery of super potent and highly selective dopamine D sub ... for the dopamine 3 D3 receptor with a novel in vivo behavioral profile journal J. Med. Chem. volume ... of piribedil for dopamine D3 receptor subtypes, an autoradiographic study journal Eur. J. Pharmacol ... url pmc 2760932 ref FAUC 365, silent Receptor antagonistantagonist , subtype selective ref name ... as selective probes with high affinity for the dopamine D3 receptor journal J. Med. Chem ... url ref SB 277011 A , selective D sub 3 sub antagonist, 80x selectivity over D sub 2 sub ... to several different drugs Domperidone D sub 2 sub and D sub 3 sub antagonist Image D3 ligands.png thumbnail left 500px Chemical structures of selective D sub 3 sub receptor ligands. Interactions Dopamine ... more details
agents in which disinhibition of norepinephrine and dopamine release is their primary mechanism ... 10.1111 j.1743 6109.2011.02595.x ref which disinhibits norepinephrine and dopamine release in the prefrontal ... also Noradrenergic and specific serotonergic antidepressant NaSSA Serotonin antagonist and reuptake ... more details
File Dopamine2.svg thumb right 200px Dopamine A dopamine reuptake inhibitor DRI , DARI is a type of drug that acts as a reuptake inhibitor for the neurotransmitter dopamine by blocking the drug action action of the dopamine transporter DAT . This in turn leads to increased extracellular concentration s of dopamine and therefore an increase in dopaminergic neurotransmission . Indications DRIs may be used in the clinical treatment of attention deficit hyperactivity disorder ADHD , narcolepsy , and fatigue medical fatigue as stimulant s, obesity as appetite suppressant s, and mood disorder s as antidepressant s. They can also be used for social phobia SP and other anxiety disorder s as anxiolytic s, in parkinsonism as antiparkinsonian agent s, for the Cancer Signs and symptoms palliation of cancer related lethargy as stimulants , in drug addiction as anticraving agent s, and to augment or reduce ... Drug interaction s such as abolished effects from dopamine releasing agent s like amphetamine ... type and mutant human dopamine transporters molecular features that differentially determine antagonist binding properties journal Journal of Neurochemistry volume 107 issue 4 pages 928 40 year ... cite journal author Zhao G, Jiang ZH, Zheng XW, Zang SY, Guo LH title Dopamine transporter ... Zhao G, Li S, Qin GW, Fei J, Guo LH title Inhibitive effects of Fructus Psoraleae extract on dopamine ... or norepinephrine transporters or any other sites. Releasing agent Dopamine releasing agent ..., there are no known selective DRAs, as dissociating affinity between the dopamine and norepinephrine ..., Blough BE, Baumann MH title Dual dopamine serotonin releasers as potential medications for stimulant ... Serotonin norepinephrine reuptake inhibitor SNRI Norepinephrine dopamine reuptake inhibitor NDRI Serotonin norepinephrine dopamine reuptake inhibitor SNDRI Discovery and development of dual serotonin ... DEFAULTSORT Dopamine Reuptake Inhibitor Category Dopamine reuptake inhibitors Category Drugs acting ... more details
File Norepinephrine structure.png thumb Norepinephrine File Dopamine2.svg thumb Dopamine A norepinephrine dopamine reuptake inhibitor NDRI is a drug that acts as a reuptake inhibitor inhibitor for the neurotransmitter s chemical nerve in the brain norepinephrine and dopamine by blocking the action of the norepinephrine transporter NET and the dopamine transporter DAT , respectively. This in turn leads to increased extracellular concentrations of both norepinephrine and dopamine and, therefore, an increase in adrenergic and dopaminergic neurotransmission . The only FDA aproved NDRI is Bupropion . Main Norepinephrine reuptake inhibitor Main Dopamine reuptake inhibitor Main Reuptake inhibitor Refer to the directly above mentioned articles for more information. File Methylphenidate.png thumb right 160px Methylphenidate File Cocaine 2D skeletal.svg thumb right 160px Cocaine See also Reuptake inhibitor Serotonin reuptake inhibitor SRI Selective serotonin reuptake inhibitor SSRI Norepinephrine reuptake inhibitor NRI Serotonin norepinephrine reuptake inhibitor SNRI Dopamine reuptake inhibitor DRI Serotonin norepinephrine dopamine reuptake inhibitor SNDRI References Reflist 2 Stimulants Antidepressants Adrenergics Dopaminergics Neuromodulation Category Norepinephrine dopamine reuptake inhibitors es Inhibidor de la recaptaci n de dopamina y noradrenalina ... more details
in the purest sense and would instead be an SDRA or serotonin dopamine releasing agent of which it would ... reuptake inhibitor See also Dopamine reuptake inhibitor See also Reuptake inhibitor See also Norepinephrine dopamine reuptake inhibitor NDRI Serotonin norepinephrine reuptake inhibitor SNRI Serotonin norepinephrine dopamine reuptake inhibitor SNDRI References Reflist Dopaminergics Serotonergics Neuromodulation Category Serotonin dopamine reuptake inhibitors es Inhibidor de la recaptaci n de dopamina ... more details
PBB geneid 1621 Dopamine hydroxylase DBH is an enzyme that converts dopamine to norepinephrine . gallery Image Dopamin Dopamine.svg Dopamine Image Norepinephrine structure.png Norepinephrine . Note extra hydroxyl group. gallery DBH is a 290 kDa copper containing oxygenase consisting of four identical subunits, and its activity requires ascorbate as a Cofactor biochemistry cofactor . ref cite journal author Rush RA, Geffen LB title Dopamine beta hydroxylase in health and disease. journal Crit Rev Clin Lab Sci. volume 12 issue 3 pages 241 77 year 1980 pmid 6998654 doi 10.3109 10408368009108731 ref It is the only enzyme involved in the synthesis of small molecule neurotransmitters that is membrane bound, making norepinephrine the only transmitter synthesized inside vesicles. It is expressed in noradrenergic nerve terminals of the central and peripheral nervous systems, as well as in chromaffin cells of the adrenal medulla. DBH is inhibited by disulfiram , ref cite journal author Goldstein M, Anagnoste B, Lauber E, McKeregham MR title Inhibition of dopamine beta hydroxylase by Disulfiram. journal Life Sci volume 3 issue 7 pages 763 7 year 1964 pmid 14203977 doi 10.1016 0024 3205 64 90031 1 ref tropolone , ref cite journal author Goldstein M, Lauber E, McKeregham MR title Inhibition of dopamine beta hydroxylase by tropolone and other chelating agents. journal Biochem Pharmacol volume 13 issue 7 pages 1103 6 year 1964 pmid 14201135 doi 10.1016 0006 2952 64 90109 1 ref and, most selectively, by nepicastat . ref cite journal unused data journal Br J Pharmacol author Stanley WC et ... inhibitor of dopamine beta hydroxylase. volume 121 issue 8 pages 1803 9 year 1997 pmid 9283721 doi ... Dopamine beta hydroxylase deficiency References references External links http www.ncbi.nlm.nih.gov bookshelf br.fcgi?book gene&part dbh GeneReviews NIH NCBI UW entry on Dopamine Beta Hydroxylase Deficiency MeshName Dopamine beta Hydroxylase Oxygenases Neurotransmitter metabolism enzymes The PBB ... more details
enzyme Name dopamine beta monooxygenase EC number 1.14.17.1 CAS number 9013 38 1 IUBMB EC number 1 14 17 1 GO code 0004500 image width caption In enzymology , a dopamine beta monooxygenase EC number 1.14.17.1 is an enzyme that catalysis catalyzes the chemical reaction 3,4 dihydroxyphenethylamine ascorbate O sub 2 sub math rightleftharpoons math noradrenaline dehydroascorbate H sub 2 sub O The 3 substrate biochemistry substrates of this enzyme are 3,4 dihydroxyphenethylamine , ascorbate , and oxygen O sub 2 sub , whereas its 3 product chemistry products are noradrenaline , dehydroascorbate , and water H sub 2 sub O . This enzyme belongs to the family of oxidoreductase s, specifically those acting on paired donors, with O2 as oxidant and incorporation or reduction of oxygen. The oxygen incorporated need not be derived from O2 with reduced ascorbate as one donor, and incorporation of one ato of oxygen into the other donor. The systematic name of this enzyme class is 3,4 dihydroxyphenethylamine,ascorbate oxygen oxidoreductase beta hydroxylating . Other names in common use include dopamine beta hydroxylase , MDBH membrane associated dopamine beta monooxygenase , SDBH soluble dopamine beta monooxygenase , dopamine B hydroxylase , oxygenase, dopamine beta mono , 3,4 dihydroxyphenethylamine beta oxidase , 4 2 aminoethyl pyrocatechol beta oxidase , dopa beta hydroxylase , dopamine beta oxidase , dopamine hydroxylase , phenylamine beta hydroxylase , and 3,4 dihydroxyphenethylamine beta mono oxygenase . This enzyme participates in tyrosine metabolism . It has 3 cofactor biochemistry cofactors copper , PQQ , and Fumarate . This protein may use the morpheein model of allosteric regulation . ref name pmid22182754 cite journal author T. Selwood and E. K. Jaffe. title Dynamic dissociating homo oligomers and the control of protein function. journal Arch. Biochem. Biophys. volume 519 issue 2 pages 131 43 year 2011 pmid 22182754 url http www.ncbi.nlm.nih.gov entrez query.fcgi?cmd Retrieve&db ... more details
File Dopamine 3d CPK.png right thumb 250px Three dimensional model of the structure of a dopamine molecule. Dopamine is at the origin of DDS. Dopamine dysregulation syndrome DDS , sometimes known as hedonistic ... with Parkinson s disease PD due to a long exposure to dopamine replacement therapy DRT . It is characterized ... , or hypersexuality . ref name pmid17988927 cite journal author Merims D, Giladi N title Dopamine ... of dopamine neuron s in the substantia nigra and a loss of dopamine in the putamen . It is described ... common treatment is dopamine replacement therapy, which consists in the administration of levodopa ... ref Dopamine has been related to the normal learning of stimuli with behavioral and motivational ... cite journal author Evans AH, Lees AJ title Dopamine dysregulation syndrome in Parkinson s disease ... media landingpage.htm?issn 1350 7540&volume 17&issue 4&spage 393 ref In accordance with the role of dopamine in reward processing, Substance dependence addictive drug s stimulate dopamine release. ref name pmid15247533 Although the exact mechanism has yet to be elucidated the role of dopamine in the reward ... of addiction have been used to explain how dopamine replacement therapy produces DDS. ref name pmid14505581 cite journal author Lawrence AD, Evans AH, Lees AJ title Compulsive use of dopamine replacement ... stages. This habituation is thought to be dopamine mediated. With long term administration of L ... to dopamine therapy. The behavioral and mood symptoms of the syndrome are produced by the dopamine ... The main prevention measure proposed is the prescription of the minimum effective dopamine dose for individuals ... features to this action. ref name pmid15247533 Cessation of dopamine agonist s therapy may also ... of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson ... name pmid5820999 During the following decades cases featuring DDS symptoms in relation to dopamine ... dysregulation in patients with Parkinson s disease on dopamine replacement therapies journal ... more details
DISPLAYTITLE N Arachidonoyl dopamine chembox Verifiedfields changed verifiedrevid 477503651 Name N Arachidonoyl dopamine ImageFile NADA.png ImageSize 200px IUPACName 5 Z ,8 Z ,11 Z ,14 Z N 2 3,4 dihydroxyphenyl ethyl icosa 5,8,11,14 tetraenamide OtherNames NADA Section1 Chembox Identifiers CASNo Ref cascite changed ?? CASNo 199875 69 9 ChEMBL Ref ebicite correct EBI ChEMBL 138921 PubChem 5282105 SMILES CCCCC C C C C C C C C C C C CCCC O NCCC1 CC C C C1 O O ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID 4445314 InChI 1 C28H41NO3 c1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 28 32 29 23 22 25 20 21 26 30 27 31 24 25 h6 7,9 10,12 13,15 16,20 21,24,30 31H,2 5,8,11,14,17 19,22 23H2,1H3, H,29,32 b7 6 ,10 9 ,13 12 ,16 15 InChIKey MVVPIAAVGAWJNQ DOFZRALJBM StdInChI Ref stdinchicite correct chemspider StdInChI 1S C28H41NO3 c1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 28 32 29 23 22 25 20 21 26 30 27 31 24 25 h6 7,9 10,12 13,15 16,20 21,24,30 31H,2 5,8,11,14,17 19,22 23H2,1H3, H,29,32 b7 6 ,10 9 ,13 12 ,16 15 StdInChIKey Ref stdinchicite correct chemspider StdInChIKey MVVPIAAVGAWJNQ DOFZRALJSA N MeSHName Section2 Chembox Properties Formula C sub 28 sub H sub 41 sub NO sub 3 sub MolarMass 439.63 g mol Appearance Density MeltingPt BoilingPt Section3 Chembox Hazards Solubility MainHazards FlashPt Autoignition N Arachidonoyl dopamine NADA is an endocannabinoid which acts as an agonist of the Cannabinoid receptor type 1 CB sub 1 sub receptor ref name Ralevic 2003 cite journal journal European journal of pharmacology year 2003 month July volume 472 issue 1 2 pages 1 21 title Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. author Ralevic V. pmid 12860468 doi 10.1016 S0014 2999 03 01813 2 ref and the TRPV1 transient receptor potential V1 TRPV1 ion channel . Its discovery was described in 2002 by an academic research group from Italy ... dopamine, N Category Cannabinoids Category Vanilloids Category Eicosanoids Category Catechols Category ... more details
Encyclopedia
top
